abilify aripiprazole 5mg tablet blister pack
otsuka australia pharmaceutical pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; maize starch; hyprolose; lactose monohydrate; microcrystalline cellulose; indigo carmine aluminium lake - - abilify is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. - acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate; - maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.
jynarque- tolvaptan kit jynarque- tolvaptan tablet
otsuka america pharmaceutical, inc. - tolvaptan (unii: 21g72t1950) (tolvaptan - unii:21g72t1950) - jynarque is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (adpkd). jynarque is contraindicated in patients: - with a history, signs or symptoms of significant liver impairment or injury. this contraindication does not apply to uncomplicated polycystic liver disease [see warnings and precautions (5.1)] - taking strong cyp 3a inhibitors - with uncorrected abnormal blood sodium concentrations [see warnings and precautions (5.3)] - unable to sense or respond to thirst [see warnings and precautions (5.3)] - hypovolemia [see warnings and precautions (5.3)] - hypersensitivity (e.g., anaphylaxis, rash) to tolvaptan or any component of the product [see adverse reactions (6)] - uncorrected urinary outflow obstruction - anuria risk summary available data with jynarque use in pregnant women are insufficient to determine if there is a drug associated risk of adverse developmental outcomes. in embryo-fetal development studies, pregnant rats a
inqovi 35/100 decitabine 35 mg and cedazuridine 100 mg tablet blister pack
otsuka australia pharmaceutical pty ltd - decitabine, quantity: 35 mg; cedazuridine, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - inqovi 35/100 is indicated for the treatment of adult patients with myelodysplastic syndromes (mds) intermediate-1, intermediate-2, and high-risk international prognostic scoring system groups, and patients with chronic myelomonocytic leukaemia (cmml).
inqovi 35/100 decitabine 35 mg and cedazuridine 100 mg tablet bottle
otsuka australia pharmaceutical pty ltd - decitabine, quantity: 35 mg; cedazuridine, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - inqovi 35/100 is indicated for the treatment of adult patients with myelodysplastic syndromes (mds) intermediate-1, intermediate-2, and high-risk international prognostic scoring system groups, and patients with chronic myelomonocytic leukaemia (cmml).
rebamipide tablets 100mg "otsuka" (レバミピド錠100mg「オーツカ」)
otsuka pharmaceutical factory, inc. - rebamipide - white tablet, diameter: 8.1 mm , thickness: 3.4 mm
raxar
glaxosmithkline nz limited - grepafloxacin hydrochloride sesquihydrate 472.8mg; - film coated tablet - 400 mg - active: grepafloxacin hydrochloride sesquihydrate 472.8mg excipient: hyprolose magnesium stearate microcrystalline cellulose opadry white
raxar
glaxosmithkline nz limited - grepafloxacin hydrochloride sesquihydrate 709.2mg; - film coated tablet - 600 mg - active: grepafloxacin hydrochloride sesquihydrate 709.2mg excipient: hyprolose magnesium stearate microcrystalline cellulose opadry white
abilify tablet 15 mg
otsuka pharmaceuticals (singapore) pte. ltd. - aripiprazole - tablet - 15 mg - aripiprazole 15 mg